Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023)

Spyre Therapeutics' Operating Leases history spans 5 years, with the latest figure at $3.8 million for Q1 2023.

  • For Q1 2023, Operating Leases fell 14.42% year-over-year to $3.8 million; the TTM value through Mar 2023 reached $3.8 million, down 14.42%, while the annual FY2022 figure was $4.0 million, 13.11% down from the prior year.
  • Operating Leases reached $3.8 million in Q1 2023 per SYRE's latest filing, down from $4.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.1 million in Q4 2020 to a low of $372000.0 in Q1 2019.
  • Average Operating Leases over 5 years is $4.4 million, with a median of $4.7 million recorded in 2019.
  • Peak YoY movement for Operating Leases: skyrocketed 1194.35% in 2020, then decreased 14.42% in 2023.
  • A 5-year view of Operating Leases shows it stood at $4.7 million in 2019, then grew by 8.85% to $5.1 million in 2020, then decreased by 10.16% to $4.6 million in 2021, then fell by 13.11% to $4.0 million in 2022, then decreased by 4.52% to $3.8 million in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Operating Leases are $3.8 million (Q1 2023), $4.0 million (Q4 2022), and $4.2 million (Q3 2022).